Phase 2 N=43 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Mantle-Cell Lymphoma
Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Phase 2 N=45 Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
Primary: Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months — 68.9 percentage of…
Phase 2 N=29 Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
Lymphocytic Leukemia · Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) — 61 percentage of participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=14 Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Phase 2 N=30 Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants
Phase 2 N=45 Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete Response + Partial Response) at the End of Cycles 3 and 6 Using the 2007 International Working Group Criteria — 71; 82 percentage of…
Phase 2 N=71 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients
Phase 2 N=39 Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Phase 2 N=10 Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma · Refractory Mantle Cell Lymphoma
Primary: Percent of Participants With Best Overall Objective Response or Complete Response/Partial Response (CR/PR) — 89 percentage of participants
Phase 3 N=280 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 15.6; 6.2 Months — p=< 0.0001
Phase 2 N=36 A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B — 1; 0; 0; 2 Participants
Phase 2 N=65 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Primary: Proportion of Patients Who Achieve a Confirmed Response — 0.0800; 0; 0 proportion of responders
Phase 2 N=12 Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…
Phase 2 N=28 Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants
Phase 2 N=254 A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma · Lymphoma, Mantle-Cell
Primary: Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review — 37.6; 22.7 weeks — p=0.012
Phase 4 N=103 Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Primary: Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections — 0; 0 Events
Phase 2 N=38 Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Overall Response Rate — 92 percentage of patients
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 2 N=161 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Lymphoma
Primary: Objective Response Rate (ORR) — 8.3; 39.0; 64.5; 71.4 percentage of participants
Phase 2 N=36 Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
Loss of Chromosome 17p · Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Number of Participants With a Response for Cohorts 1 and 3 — 5; 10 Participants
Phase 2 N=57 Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Indolent Adult Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 97; 39 percentage of participants
Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
Phase 3 N=160 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — NA; 8.38 months — p=<0.0001
Phase 2 N=36 Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting…
Phase 2 N=13 Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…